National Institute on Drug Abuse (NIDA)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute on Drug Abuse (NIDA) sits in the top decile of US sponsors by registered trial count (#108 of 15,742 sponsors by registered trial count).
National Institute on Drug Abuse (NIDA): 335 sponsored US clinical trials, 14 recruiting.
National Institute on Drug Abuse (NIDA) sponsors 335 registered US clinical trials on ClinicalTrials.gov, 14 of them currently recruiting, and 292 completed. 30 of these trials are in Phase 3-4 (later-stage) and 202 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cocaine-Related Disorders, with 17 trials.
Top-decile sponsor footprint
National Institute on Drug Abuse (NIDA) ranks in the top decile of sponsors by registered trial count (#108 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
292 of 316 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
335 total, page 4 of 7
Effectiveness of Bupropion for Treating Nicotine Dependence in Young People
NCT00129272
Examining the Effectiveness of the Nicotine Patch in Male and Female Smokers - 2
NCT00135746
Buprenorphine as a Treatment for Individuals Dependent on Analgesic Opioids
NCT00218101
A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder
NCT00593099
Neurobiology and Pharmacokinets of Acute MDMA Administration
NCT01148342
Treatment of Heroin and Cocaine With Methadone Maintenance and Contingency Management
NCT00292110
Behavioral Smoking Cessation Treatment - 1
NCT00110825
Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1
NCT00218556
Contingency Management for Attendance - 2
NCT00249639
Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia
NCT00218231
An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users
NCT00841477
Opioid Agonist and Antagonist Effects on Opioid Dependence
NCT00142727
Positive Choice: Prevention for Positive Health
NCT00447707
Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11
NCT00015301
A Transtheoretical Model Group Therapy for Cocaine
NCT00178776
Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder - 2
NCT00135772
Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals
NCT00218309
Chronic Hepatitis Intervention Project for Drug Users
NCT00596843
Real Time Assessment of Drug Craving, Use, and Abstinence During Outpatient: A Development and Feasibility Study
NCT00292136
Automatic Versus Evaluative Components of Cue Reactivity
NCT01036126
Vouchers vs. Prizes for Methadone Patients - 1
NCT00249522
Quantitation of Human Cerebral Nicotinie Receptors With 2[18F]FA-85380 and PET Healthy Non-smokers and Ex-Smokers and in Heavy and Light Situational Smokers
NCT01038245
Bupropion for the Treatment of Methamphetamine Dependence - 1
NCT00069251
Modifying Group Therapy for Bipolar Substance Abusers - 1
NCT00227838
Assessment of Potential Interactions Between Cocaine and RPR 102681 - 1
NCT00067535
Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1
NCT00249574
Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug Users
NCT00194480
Naltrexone as Adjunct in Alcoholic Cocaine Dependent Patients - 4
NCT00000307
Effectiveness of N-acetylcysteine in Treating Cocaine Dependent Individuals - 1
NCT00136825
Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1
NCT00218530
Effectiveness of Self-Help for Dually-Diagnosed Persons - 1
NCT00218582
Comparison of Buprenorphine and Methadone - 3
NCT00000334
Cocaethylene as a Treatment for Cocaine Dependence - 1
NCT00124696
Effectiveness of Using Tobacco Free Snuff in Reducing Negative Effects of Smokeless Tobacco Use
NCT00218270
Maintaining Abstinence in Chronic Cigarette Smokers - 1
NCT00087880
Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals
NCT00870792
Tiagabine for the Treatment of Cocaine Dependence - 1
NCT00086255
Effects of Nicotine on Cognitive Task Performance and Brain Activity as Measured by fMRI
NCT01036711
Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone
NCT00000243
Effects of Nicotine on Brain Activity as Measured by fMRI
NCT01037153
Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug Abusers
NCT00685620
Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome
NCT00510016
Combination Pharmacotherapy for Smoking Cessation Among Methadone Patients
NCT00060814
Study to Reduce Intravenous Exposures (STRIVE)
NCT00391482
Ondansetron for the Treatment of Methamphetamine Dependence - 1
NCT00040053
Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia
NCT00218218
Nicotine Replacement Treatment for Pregnant Smokers - 1
NCT00115687
Effectiveness of Various Smoking Cessation Therapies in Reducing Smoking in Adolescents - 1
NCT00158171
Effects of Buspirone in Opiate Withdrawal
NCT00326235
Incentive Programs for Female Substance Abusers Who Smoke - 3
NCT00064922
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 81 |
| Phase 2 | 121 |
| Phase 3 | 14 |
| Phase 4 | 16 |
What is open in the National Institute on Drug Abuse (NIDA) pipeline
14 recruiting of 335 indexed (4% open); 292 completed (87%).
Phase mix: 30 late (III/IV) vs 202 early (I/II) (early-phase heavy).
Top condition: Cocaine-Related Disorders (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute on Drug Abuse (NIDA): open-pipeline peers nationwide
Peers matched on 335 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
National Institute on Drug Abuse (NIDA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 335 trials (± recruiting share)
- Biogen · 334 trials · 6% recruiting
- National Institutes of Health Clinical Center (CC) · 338 trials · 7% recruiting
- Genentech · 332 trials · 7% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Akebia Therapeutics · 4% recruiting · 24 trials
- Dentsply Sirona Implants and Consumables · 4% recruiting · 24 trials
- Smith & Nephew · 4% recruiting · 72 trials
- Medtronic - MITG · 4% recruiting · 119 trials
Related
What to do with this National Institute on Drug Abuse (NIDA) page
335 registered trials is a research-attention snapshot, not an endorsement of National Institute on Drug Abuse (NIDA) or any single study.
- 14 of National Institute on Drug Abuse (NIDA)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cocaine-Related Disorders is the condition National Institute on Drug Abuse (NIDA) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cocaine-Related Disorders trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute on Drug Abuse (NIDA) pipeline card: 335 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.